Novo Nordisk plans 9,000 job cuts (11.5% of workforce) to save $1.26B annually.
5,000 cuts in Denmark, with 78,400 global employees.
CEO Mike Doustdar acknowledges market changes and resource reallocation.
Operating profit growth forecast reduced to 4–10% due to restructuring.